Akebia Therapeutics (Cincinnati, OH) a clinical-stage biopharmaceutical company focused on the development of small-molecules for anemia and vascular disease, closed a $16M Series A bringing the total financing to $25M. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital.

FerroKin Biosciences (San Carlos, CA) early-stage developer of iron chelator for treatment of anemias, closed a $15M Series A financing. Participants include Clarus Ventures, Burrill & Co. and Celegene Inc.